The European Hematology Association (EHA)

The European Hematology Association (EHA) is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.

Acalabrutinib, a Second-Generation BTK Inhibitor, Is Active in Previously Untreated CLL

EHA 2016, EHA 2016 – Leukemia

Acalabrutinib is a second-generation inhibitor of Bruton’s tyrosine kinase (BTK) that is currently being evaluated in patients with previously untreated and relapsed chronic lymphocytic leukemia (CLL), as well as other hematologic malignancies. Researchers report phase 1/2 study results for acalabrutinib, including overall response rates, rates of treatment-related lymphocytosis, bleeding risk, and other safety details. Read More ›

Ibrutinib Results in Robust Clinical Activity and Survival Outcomes in Difficult-to-Treat CLL Populations

EHA 2016

Patients with deletion 17p chronic lymphocytic leukemia (CLL) have aggressive disease and poor outcomes with chemoimmunotherapy. Ibrutinib, a once-daily therapy that inhibits Bruton’s tyrosine kinase, is approved for previously untreated patients with CLL, including patients with deletion 17p. This cross-study analysis of efficacy and tolerability outcomes for ibrutinib reports 2+-year data in this high-risk subset of patients. Read More ›

The European Hematology Association (EHA)

Page 6 of 6